The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis
Q Tang, W Pan, L Peng - Frontiers in Endocrinology, 2022 - frontiersin.org
Introduction The dipeptidyl peptidase-4 inhibitor (DPP-4i) drugs, such as evogliptin, as the
second-line drugs for type 2 diabetes mellitus (T2DM) treatment have been reported to …
second-line drugs for type 2 diabetes mellitus (T2DM) treatment have been reported to …
The Study of Hypoglycemic Activity of 7-Terpenylcoumarins
S Kuranov, M Marenina, D Ivankin, M Blokhin… - Molecules, 2022 - mdpi.com
Natural and synthetic coumarins are often considered privileged scaffolds for obtaining
pharmacological agents with hypoglycemic activity. Chemical modification of coumarins …
pharmacological agents with hypoglycemic activity. Chemical modification of coumarins …
Discovery, synthesis and in combo studies of Schiff's bases as promising dipeptidyl peptidase-IV inhibitors
R Abu Khalaf, M Awad, L Al-Essa, S Mefleh… - Molecular Diversity, 2021 - Springer
Diabetes mellitus is a main global health apprehension. Macrovascular illnesses,
neuropathy, retinopathy, and nephropathy are considered some of its severe hitches …
neuropathy, retinopathy, and nephropathy are considered some of its severe hitches …
GLP-1 Targeted Novel 3-phenyl-7-hydroxy Substituted Coumarins Mitigate STZ-induced Pancreatic Damage and Improve Glucose Homeostasis in OGTT Method
Background: Worldwide, type 2 diabetes mellitus accounts for a considerable burden of
disease, with an estimated global cost of> 800 billion USD annually. For this reason, the …
disease, with an estimated global cost of> 800 billion USD annually. For this reason, the …